Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing in…
Go to Source
Author: GenSight Biologics
GenSight Biologics Confirms Definitive Full-Year 2024 Consolidated Financial Results Are in Line with Estimates
